Abstract
Selection of cytostatic agents for intrathecal administration is the subject of this paper.
Both the toxic side effects—destruction of blood-brain barrier and change of body weight—and the cytostatic effects on intracranially transplanted Yoshida ascites sarcoma were investigated of intrathecal administration of various cytostatic agents. As a result, it may be concluded that Methotrexate and Endoxan and lower dose of mitomycin C are suitable drugs for intrathecal chemotherapy.
Based on these findings, clinical cases of malignant brain tumours were treated with intrathecal chemotherapy.
Grateful acknowledgement is made to Professor Dennosuke Jinnai for his constant interest and guidance in this investigation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Hayakawa, T., Yamada, R., Kanai, N. et al. Intrathecal Chemotherapy. Br J Cancer 24, 489–497 (1970). https://doi.org/10.1038/bjc.1970.59
Issue Date:
DOI: https://doi.org/10.1038/bjc.1970.59
This article is cited by
-
Interstitial chemotherapy for brain tumors: review
Journal of Neuro-Oncology (1991)